<DOC>
	<DOCNO>NCT00048464</DOCNO>
	<brief_summary>Patients immune cell collect expand outside body . Patients undergo standard treatment high dose chemotherapy follow peripheral blood stem cell transplantation . Three day follow transplant , patient receive infusion large number expand immune cell . The goal study determine safety well potential efficacy treatment .</brief_summary>
	<brief_title>T Cell Immunotherapy Multiple Myeloma Patients Undergoing Bone Marrow Transplant</brief_title>
	<detailed_description>This Phase I/II clinical study design examine safety Xcellerated T Cells , activate , autologous T cell product , study subject undergo autologous peripheral blood stem cell transplant treatment multiple myeloma . Thirty-five patient treat . Patients must undergo induction therapy prior study registration , may progress follow induction therapy prior therapy myeloma . Patients undergo steady state leukapheresis ( Xcellerate Leukapheresis ) obtain peripheral blood mononuclear cell use produce Xcellerated T Cells . During Xcellerate Process , T cell activate expanded ex vivo co-stimulation anti-CD3 anti-CD28 monoclonal antibody covalently attach super-paramagnetic microbeads . While Xcellerated T Cells produce Xcyte Therapies , patient treat standard mobilization regimen consist cyclophosphamide filgrastim ( Neupogen ; G-CSF ) , follow second leukapheresis collection peripheral blood stem cell . Patients treated standard high-dose chemotherapy regimen multiple myeloma consist single agent melphalan ( 200mg/m2 ) . Patients receive peripheral blood stem cell follow post-transplant filgrastim neutrophil recovery . Three day ( Day 3 ) follow stem cell infusion , patient receive single dose Xcellerated T Cells .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Patient Inclusion Criteria Previous diagnosis multiple myeloma base standard criterion . Tests need perform within 30 day registration . DurieSalmon Stage II III disease time since diagnosis Induction therapy minimum 3 cycle chemotherapy 3 month highdose corticosteroid without progressive disease . ( Note : glucocorticoid allow within 3 week registration ; see exclusion criterion . ) Measurable serum and/or urine Mprotein prior induction therapy document available Lymphocyte subset flow cytometry demonstrate CD3+ &gt; = 10 % peripheral white blood cell count , CD4+/CD8+ &gt; = 0.30 . Test must obtain follow completion induction therapy . Meets institutional criterion institutional approval undergo autologous peripheral blood stem cell transplantation Age &gt; = 18 year old &lt; =70 year old ECOG performance status 0 1 Life expectancy &gt; 6 month Females childbearing potential must negative serum bHCG test willing use effective contraception ( i.e . hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) Day 180 . Negative test result current/active infection HIV1 , HIV2 , hepatitis B , hepatitis C within 60 day registration . ( Antibody , antigen nucleic acid test acceptable , depend institutional standard . ) Corrected serum calcium &lt; 11 mg/dL , evidence symptomatic hypercalcemia . ( Corrected serum calcium calculate add 0.8 mg/dL measure serum calcium every 1 g/dL serum albumin fall 4.0 g/dL . ) Serum total bilirubin SGPT ( ALT ) &lt; 2.0 time upper limit normal Serum creatinine &lt; 2.0 mg/dL No detectable human antimouse antibody ( HAMA ) titer , history allergy mice murine ( mouse ) proteins The patient must able comprehend sign informed consent Patient Exclusion Criteria Diagnosis follow cancer : POEMS syndrome ( plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein [ Mprotein ] skin change ) Nonsecretory myeloma Plasma cell leukemia Diagnosis amyloidosis Progression relapse presently past , follow therapy multiple myeloma Previous hematopoietic stem cell transplantation Use corticosteroid ( glucocorticoid ) within 21 day registration Infection require treatment antibiotic , antifungal , antiviral agent within seven day registration Participation clinical trial , within four week prior registration trial , involved investigational drug device History malignancy multiple myeloma within five year registration , except adequately treat basal squamous cell skin cancer . Any exception must discuss Xcyte Therapies ’ Medical Monitor prior registration . History autoimmune disease ( e.g. , rheumatoid arthritis , multiple sclerosis , systemic lupus erythematosis ) require systemic treatment . Hypothyroidism without evidence Grave ’ Disease Hashimoto ’ thyroiditis permit . Evidence spinal cord compression Major organ system dysfunction include ( limited ) : New York Heart Association Class III IV , pulmonary disease require use inhale steroid bronchodilator , renal , hepatic , gastrointestinal , neurologic , psychiatric dysfunction would impair patient ’ ability participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>T Cell Therapy</keyword>
	<keyword>Peripheral Blood Stem Cell Transplant</keyword>
	<keyword>Bone marrow transplant</keyword>
	<keyword>Adoptive immunotherapy</keyword>
	<keyword>Xcellerate</keyword>
</DOC>